Neupulse (Neurotherapeutics Ltd) is a UK neurotechnology company developing a wearable wrist device for non-invasive neuromodulation to treat Tourette Syndrome. Founded in 2021 as a spin-out from the University of Nottingham, the company commercializes research by Professor Stephen Jackson, Professor Georgina Jackson, and Dr. Barbara Morera.

The device delivers gentle, rhythmic electrical stimulation of the median nerve in the wrist, targeting specific brain networks associated with tic generation. The approach is based on over two decades of neuroscience research demonstrating that peripheral nerve stimulation can modulate central motor circuitry involved in tic disorders. Clinical trials have shown significant reductions in both tic frequency and the urge to tic for motor and vocal tics, with a 25% reduction on initial use.

Neupulse's device is designed for on-demand, patient-controlled use as a drug-free therapeutic alternative. NICE has recommended the device for use in the NHS, marking the first time a digital therapy has been recommended for Tourette's in the UK. The company has raised GBP 3 million in funding, is planning commercial launch in mid-2026, and is a founding member of the N3 Centre for Neurotechnology at the University of Nottingham. Pre-orders are currently live for UK customers.